Page 4 of 9, showing 50 records out of 429 total, starting on record 151, ending on 200
| Publication |
Category |
Year |
|
806. El-Alfy, M., Luu-The, V., Huang, X.F., Berger, L., Labrie, F., Pelletier, G. (1999) Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology, 140: 1481-1491. |
Intracrinology |
1999 |
|
417. Gutman, M., Couillard, S., Labrie, F., Candas, B., Labrie, C. (1999) Effects of the antiestrogen EM-800 (SCH 57050) and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 5176-5180. |
Intracrinology |
1999 |
|
418. Hida, N., Poulin, R., Veilleux, R., Labrie, F. (1999) Differential androgen sensitivity is associated with clonal heterogeneity in steroid metabolism, ornithine decarboxylase regulation and IL-1alpha action in mouse mammary tumor cells. J. Steroid Biochem. Mol. Biol., 71: 71-81. |
Intracrinology |
1999 |
|
59. Labrie, F. (1999) Combined androgen blockade: its unique efficacy for the treatment of localized prostate cancer, in: De Vita, V.T., Hellman, S. et Rosenberg, S.A., eds: Cancer: Principles and Practice of Oncology, Philadelphia, Lippincott-Raven, pp 1-9. |
Intracrinology |
1999 |
|
810. Labrie, F. (1999) Internal symposium: Editorial. Xth International Congress on Hormonal Steroids (Quebec City, Canada 17-21 June 1998). J. Steroid Biochem. Mol. Biol., 69: 1. |
Intracrinology |
1999 |
|
611. Labrie, F. (1999) Potential of DHEA as hormone replacement therapy, in Reproductive Medicine: Past Present and Future. Proceeding of the 10th World Congress on Human Reproduction, Salvador, Bahia, Brazil, Parthenon Publishing, pp 224-237. |
Intracrinology |
1999 |
|
60. Labrie, F. (1999) Prostate cancer: Endocrinology of prostate cancer-intracrinology, in: Pinchera, A., Bertega, X., Binder, C., Fischer, J. et Braverman, L., eds: Textbook of Clinical Endocrinology, Milan, Italy, McGraw-Hill Libri Italia Srl, pp 13-16. |
Intracrinology |
1999 |
|
61. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Lin, S.-X., Candas, B., Cusan, L. (1999) Impact de l'intracrinologie dans la thérapeutique et la prévention des cancers du sein et de la prostate et de la ménopause, in: Guérité, N. et Leclère, J., eds: Mises au point cliniques d'endocrinologie, nutrition et métabolisme 1999, Paris, France, Les Éditions de Médecine Pratique, pp 169-204. |
Intracrinology |
1999 |
|
612. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Lin, S.-X. (1999) DHEA, the precursor of androgens and estrogens in peripheral tissues in the human: intracrinology, in: Kalimi, M. et Regelson, W., eds: Dehydroepiandrosterone (DHEA) Biochemical, Physiological and Clinical Aspects, Berlin, New York, Walter de Gruyter, pp 299-342. |
Intracrinology |
1999 |
|
613. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Lin, S.-X., Cusan, L., Labrie, C. (1999) Role of DHEA transformation into androgens and estrogens in peripheral intracrine tissues, in: Thijssen, J.H.H. et Nieuwenhuyse, H., eds: DHEA a comprehensive review (Proceedings Workshop, Amsterdam 1997), New York, Parthenon Publishing, pp 69-103. |
Intracrinology |
1999 |
|
62. Labrie, F., Candas, B. (1999) Bicalutamide versus Flutamide in combination therapy [Letter to the Editor re: Schellhammer et al. 50: 330-336, 1997]. Urology, 53: 662-663. |
Intracrinology |
1999 |
|
66. Labrie, F., Cusan, J., Gomez, J., Levesque, J., Candas, B. (1999) Screening and treatment of localized prostate cancer decreases mortality: first analysis of the first prospective and randomized study on prostate cancer screening. Society of the Study of the Aging Male, 2: 33-43. |
Intracrinology |
1999 |
|
420. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Gauthier, S., Luu-The, V., Mérand, Y., Giguère, V., Candas, B., Luo, S., Martel, C., Singh, S.M., Fournier, M., Coquet, A., Richard, V., Charbonneau, R., Charpenet, G., Tremblay, A., Tremblay, G., Cusan, L., Veilleux, R. (1999) EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 69: 51-84. |
Intracrinology |
1999 |
|
821. Labrie, F., Simard, J., Pasqualini, J.R. (1999) Potential of DHEA as hormonal replacement therapy, 486 pages. |
Intracrinology |
1999 |
|
422. Pelletier, G., Luu-The, V., Charbonneau, A., Labrie, F. (1999) Cellular localization of estrogen receptor beta messenger ribonucleic acid in cynomolgus monkey reproductive organs. Biol. Reprod., 61: 1249-1255. |
Intracrinology |
1999 |
|
4726. Pelletier, G., Luu-The, V., Tetu, B., Labrie, F. (1999) Immunocytochemical localization of type 5 17beta-hydroxysteroid dehydrogenase in human reproductive tissues. J. Histochem Cytochem., 47: 731-738. |
Intracrinology |
1999 |
|
615. Tchernof, A., Labrie, F., Després, J.P. (1999) DHEA, obesity and cardiovascular disease, in: Kalimi, M. et Regelson, W., eds: Dehydroepiandrosterone (DHEA) Biochemical, Physiological and Clinical Aspects, Berlin, Walter de Gruyter, pp 191-213. |
Intracrinology |
1999 |
|
825. Tremblay, A., Tremblay, G.B., Labrie, F., Giguère, V. (1999) Ligand-independent recruitment of SRC-1 to estrogen receptor Beta through phosphorylation of activation function AF-1. Mol. Cell., 3: 513-519. |
Intracrinology |
1999 |
|
424. Tremblay, G.B., Tremblay, A., Labrie, F., Giguère, V. (1999) Dominant activity of activation function-1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor α⁄β heterodimeric complex. Mol. Cell. Biol., 19: 1919-1927. |
Intracrinology |
1999 |
|
827. Tremblay, M.R., Luu-The, V., Leblanc, G., Noël, P., Breton, E., Labrie, F., Poirier, D. (1999) Spironolactone-related inhibitors of type II 17Beta-hydroxysteroid dehydrogenase: Chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities. Bioorg. Med. Chem., 7: 1013-1023. |
Intracrinology |
1999 |
|
70. van der Kwast, T.H., Labrie, F., Têtu, B. (1999) Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy. Hum. Pathol., 30: 1503-1507. |
Intracrinology |
1999 |
|
72. van der Kwast, T.H., Têtu, B., Candas, B., Gomez, J.-L., Cusan, L., Labrie, F. (1999) Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology, 53: 523-529. |
Intracrinology |
1999 |
|
830. Zhu, D.-W., Campbell, R., Labrie, F., Lin, S.-X. (1999) Crystallization and preliminary crystal structure of the complex of 17Beta-hydroxysteroid dehydrogenase with a dual-site inhibitor. J. Steroid Biochem. Mol. Biol., 70: 229-235. |
Intracrinology |
1999 |
|
73. Chen, C., Li, X., Singh, S.M., Labrie, F. (1998) Activity of 17beta-(N-alkyl/arylformamido)- and 17beta-[(N-alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors in the hamster flank organ and ear. J. Invest. Dermatol., 111: 273-278. |
Intracrinology |
1998 |
|
832. Coquet, A., Boudreau, N., Merand, Y., Labrie, F. (1998) Validated high-performance liquid chromatographic methods for quantitation of a novel nonsteroidal antiestrogen. J. Chromatogr. A, 828: 247-258. |
Intracrinology |
1998 |
|
425. Couillard, S., Gutman, M., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (1998) Comparison of the effects of the antiestrogens EM-800 and Tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res., 58: 60-64. |
Intracrinology |
1998 |
|
426. Couillard, S., Labrie, C., Bélanger, A., Candas, B., Pouliot, F., Labrie, F. (1998) Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts. J. Natl. Cancer Inst., 90: 772-778. |
Intracrinology |
1998 |
|
75. Labrie, F. (1998) Combined androgen blockade and treatment of localized prostate cancer: a real hope when approaching the year 2000. Endocrine-Related Cancer, 5: 341-351. |
Intracrinology |
1998 |
|
617. Labrie, F. (1998) DHEA as physiological replacement therapy at menopause. J. Endocrinol. Invest., 21: 399-401. |
Intracrinology |
1998 |
|
76. Labrie, F. (1998) Optimizing combined androgen blockade in prostate cancer, in: Belldegrun, A., Kirby, R.S. et Oliver, R.T.D., eds: New Perspectives in Prostate Cancer, England, ISIS Medical Media, pp 293-311. |
Intracrinology |
1998 |
|
77. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J.L., Candas, B. (1998) DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids, 63: 322-328. |
Intracrinology |
1998 |
|
428. Luo, S., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (1998) Prevention of development of dimenthylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH 57050). Breast Cancer Res. Treat., 49: 1-11. |
Intracrinology |
1998 |
|
429. Luo, S., Sourla, A., Labrie, C., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, F. (1998) Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice. Endocrinology, 139: 2645-2656. |
Intracrinology |
1998 |
|
430. Martel, C., Labrie, C., Bélanger, A., Gauthier, S., Mérand, Y., Li, X., Provencher, L., Candas, B., Labrie, F. (1998) Comparison of the effects of the new orally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse. Endocrinology, 139: 2486-2492. |
Intracrinology |
1998 |
|
431. Martel, C., Provencher, L., Li, X., St-Pierre, A., Leblanc, G., Gauthier, S., Mérand, Y., Labrie, F. (1998) Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors. J. Steroid Biochem. Mol. Biol., 64: 199-205. |
Intracrinology |
1998 |
|
432. Martel, C., Sourla, A., Pelletier, G., Labrie, C., Fournier, M., Picard, S., Li, S., Stojanovic, M., Labrie, F. (1998) Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat. J. Endocrinol., 157: 433-442. |
Intracrinology |
1998 |
|
78. Pelletier, G., Luu-The, V., Huang, X.F., Lapointe, H., Labrie, F. (1998) Localization by in situ hybridization of steroid 5alpha-reductase isozyme gene expression in the human prostate and preputial skin. J. Urol., 160: 577-582. |
Intracrinology |
1998 |
|
620. Sourla, A., Flamand, M., Bélanger, A., Labrie, F. (1998) Effect of dehydroepiandrosterone on vaginal and uterine histomorphology in the rat. J. Steroid Biochem. Mol. Biol., 66: 137-149. |
Intracrinology |
1998 |
|
433. Sourla, A., Martel, C., Labrie, C., Labrie, F. (1998) Almost exclusive androgenic action of dehydroepiandrosterone in the rat mammary gland. Endocrinology, 139: 753-764. |
Intracrinology |
1998 |
|
434. Tremblay, A., Tremblay, G.B., Labrie, C., Labrie, F., Giguère, V. (1998) EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors α and beta. Endocrinology, 139: 111-118. |
Intracrinology |
1998 |
|
435. Tremblay, G.B., Tremblay, A., Labrie, F., Giguère, V. (1998) Ligand-independent activation of the estrogen receptors α and beta by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res., 58: 877-881. |
Intracrinology |
1998 |
|
80. van der Kwast, T., Têtu, B., Suburu, E.R., Gomez, J., Lemay, M., Labrie, F. (1998) Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: evidence for self-renewal of luminal cells. J. Pathol., 186: 406-409. |
Intracrinology |
1998 |
|
438. Gauthier, S., Caron, B., Cloutier, J., Dory, Y.L., Favre, A., Larouche, D., Mailhot, J., Ouellet, C., Schwerdtfeger, A., Leblanc, G., Martel, C., Simard, J., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) (S)-(+)-[4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl]-2,2-dimethylpropanoate (EM-800): a highly potent, specific and orally active non-steroidal antiestrogen. J. Med. Chem., 40: 2117-2122. |
Intracrinology |
1997 |
|
622. Labrie, F., Bélanger, A., Cusan, L., Candas, B. (1997) Physiological changes in DHEA are not reflected by the serum levels of active androgens and estrogens but of their metabolites: intracrinology. J. Clin. Endocrinol. Metab., 82: 2403-2409. |
Intracrinology |
1997 |
|
623. Labrie, F., Bélanger, A., Cusan, L., Gomez, J.L., Candas, B. (1997) Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J. Clin. Endocrinol. Metab., 82: 2396-2402. |
Intracrinology |
1997 |
|
83. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Bélanger, A., Candas, B. (1997) Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer. Mol. Urol., 1: 253-261. |
Intracrinology |
1997 |
|
624. Labrie, F., Diamond, P., Cusan, L., Gomez, J.L., Bélanger, A., Candas, B. (1997) Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J. Clin. Endocrinol. Metab., 82: 3498-3505. |
Intracrinology |
1997 |
|
855. Labrie, F., Luu-The, V., Lin, S.-X., Labrie, C., Simard, J., Breton, R., Bélanger, A. (1997) The key role of 17beta-HSDs in sex steroid biology. Steroids, 62: 148-158. |
Intracrinology |
1997 |
|
85. Labrie, F., Simard, J., Candas, B. (1997) Reply by the authors to: Editorial comment of: Comparison of in vitro effects of the pure antiandrogens OH-Flutamide, Casodex and Nilutamide on androgen-sensitive parameters [Reply to the authors/P.F. Schellhammer]. Urology, 49: 586-589. |
Intracrinology |
1997 |
|
857. Lourdusamy, M., Coté, J., Laplante, S., Labrie, F., Singh, S.M. (1997) Synthesis and in vitro Study of 17beta-(N-Ureylne-N, N'-disubstituted)-4-methyl-4Aza-5alpha-androstan-3-ones as Selective Inhibitors of Type I 5alpha-Reductase. Bioorg. Med. Chem., 5: 305-310. |
Intracrinology |
1997 |